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Chronic lymphocytic leukemia (CLL) is a variable disease; therefore, markers to identify
aggressive forms are essential for patient management. Here, we have shown that
expression of the costimulatory molecule and microbial sensor SLAMF1 (also known as
CD150) is lost in a subset of patients with an aggressive CLL that associates with a shorter
time to first treatment and reduced overall survival. SLAMF1 silencing in CLL-like Mec-1
cells, which constitutively express SLAMF1, modulated pathways related to cell migration,
cytoskeletal organization, and intracellular vesicle formation and recirculation. SLAMF1
deficiency associated with increased expression of CXCR4, CD38, and CD44, thereby
positively affecting chemotactic responses to CXCL12. SLAMF1 ligation with an agonistic
monoclonal antibody increased ROS accumulation and induced phosphorylation of p38,
JNK1/2, and BCL2, thereby promoting the autophagic flux. Beclin1 dissociated from BCL2
in response to SLAMF1 ligation, resulting in formation of the autophagy macrocomplex,
which contains SLAMF1, beclin1, and the enzyme VPS34. Accordingly, SLAMF1-silenced
cells or SLAMF1lo primary CLL cells were resistant to autophagy-activating therapeutic
agents, such as fludarabine and the BCL2 homology domain 3 mimetic ABT-737. Together,
these results indicate that loss of SLAMF1 expression in CLL modulates genetic pathways
that regulate chemotaxis and autophagy and that potentially affect drug responses, and
suggest that these effects underlie unfavorable clinical outcome experienced by SLAMF1lo
patients.
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Introduction
Chronic lymphocytic leukemia (CLL), the most common form 
of adult leukemia in Europe and North America, is character-
ized by the expansion of a population of mature B-lymphocytes 
that accumulate in the BM, lymphoid tissues, and the blood (1). 
Because of the highly variable course of the disease, molecular 
and genetic markers are important predictors of prognosis. Iden-
tification of aggressive CLL is currently based on the presence 
of genetic lesions, including deletions or mutations in the TP53, 
ATM, NOTCH1, and SF3B1 genes (2). Patients with aggressive 
CLL are also characterized by the absence of mutations in the 
immunoglobulin heavy chain V (IGHV) genes and by the expres-
sion of CD38 and CD49d, among other markers (3–5). Instead, 
the only genetic abnormalities characteristic of CLL cases with 
a favorable prognosis are deletions at chromosome 13q14 (6, 7). 
This type of deletion involves microRNA-15 and -16, which tar-
get the antiapoptotic molecule BCL2 (8). Accordingly, the major-
ity of CLL patients are characterized by a constitutively elevated 
expression of BCL2, suggesting that resistance to apoptosis plays 
an important role in the disease. This inference is supported by 
the clinical benefits obtained using drugs that target BCL2 in the 
management of these patients (9).
Autophagy is a membrane-trafficking mechanism that delivers 
cytoplasmic constituents into the lysosome for bulk degradation (10, 
11). Basal autophagy is constitutively active at low levels in most tis-
sues and maintains protein and organelle quality through the selec-
tive elimination of damaged intracellular material. The autophagy 
pathway is dramatically upregulated in response to stress and star-
vation, where it plays a critical role in removing damaged organelles 
and aggregated proteins, whose accumulation is toxic (12). Activa-
tion of autophagy relies on the formation of a molecular macrocom-
plex that contains the scaffold protein beclin1 (or ATG6) and the 
class III phosphatidyl inositol 3-kinase (PIK3C3 or VPS34), among 
other molecules. Under physiological conditions, the BH3 domain of 
beclin1 is bound to and inhibited by BCL2. This interaction can be 
disrupted by phosphorylation of BCL2, providing a molecular con-
nection between autophagy and apoptosis (13). In cancer, autophagy 
plays dual roles, acting both as a tumor suppressor mechanism — by 
preventing accumulation of damaged proteins and organelles — 
and as a prosurvival mechanism, promoting tumor growth (14, 15). 
In addition, recent findings obtained in patients with diffuse large 
B cell lymphoma indicate that low expression of beclin1 is associated 
to resistance to conventional chemotherapy regimens (16), suggest-
ing that failed activation of autophagy may condition therapeutic 
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ship between gene transcription and 
surface expression of the protein (r = 0.7, 
Supplemental Figure 1C).
These results indicate that, unlike 
normal circulating CD19+/CD5+ B-lym-
phocytes, CLL cells express heteroge-
neous levels of SLAMF1, from which it 
is reasonable to infer that a proportion 
of CLL clones lost SLAMF1 expression 
during tumor transformation.
SLAMF1 expression is lost in a subset of patients with an aggres-
sive form of CLL. The distribution of SLAMF1 was then analyzed 
according to clinical and molecular parameters. When the data was 
stratified based on the stage of the disease, it was apparent that 
SLAMF1 expression levels were markedly higher in stage A than in 
stage B and C patients combined (Figure 1D). Similarly, untreated 
patients were characterized by considerably higher SLAMF1 levels 
than treated ones, in line with the hypothesis that SLAMF1 marks 
a subset of patients with an indolent form of the disease. This dif-
ference was even more marked when considering patients who had 
not been administered therapy for at least 60 months, as opposed 
to those who received therapy within one year from diagnosis (Fig-
ure 1E). These findings were confirmed by stratifying the cohort 
according to molecular markers. In each case, SLAMF1 levels were 
lower in the subset of patients bearing markers of unfavorable 
prognosis (such as the absence of somatic mutations in the IGHV 
genes or the expression of CD38 or CD49d) than in the counterpart 
(Figure 1F). Consistently, SLAMF1 levels were higher in patients 
with favorable cytogenetics (del13q14 as sole genetic abnormality 
or no abnormalities), as opposed to patients with del11q or del17p 
considered together (Figure 1F). Together, these data indicate that 
SLAMF1 expression clearly associates to a subset of patients with a 
more favorable prognosis.
By applying recursive-partitioning analysis, the optimal 
SLAMF1 cut-off within the CLL population under study was defined 
at 6% (Supplemental Figure 2), with 233 patients considered 
SLAMF1+ and 45 SLAMF1– (16%). Treatment-free survival (TFS) 
was significantly shorter for patients expressing SLAMF1 ≤ 6% 
cut-off, with a median TFS of 2.2 years versus 7.6 in patients who 
expressed SLAMF1 in > 6% (Figure 1G and Table 1). Similar results 
were observed when considering overall survival (OS). Median OS 
was not reached, with a 77.5% survival rate at 10 years in SLAMF1– 
patients, compared with 94.7% in SLAMF1+ ones (Figure 1G and 
Table 1). Together, these results suggest that SLAMF1 expression is 
lost in a subset of CLL patients characterized by an aggressive dis-
ease with a shorter TFS and a lower OS.
SLAMF1 silencing modulates expression of genes involved in migra-
tion and intracellular vesicle formation. We then focused on the role 
of SLAMF1 in CLL cells by exploiting the cell line Mec-1, which was 
originally derived from a CLL patient and which is constitutively 
SLAMF1+. SLAMF1 was silenced using RNA interference (Mec-1/
SLAMF1sh). Mec-1 cells were transfected with 3 SLAMF1-specific 
shRNAs (Supplemental Figure 3, A and B) and with a scrambled 
shRNA (Mec-1/Ctrlsh) and were selected by cell sorting and cloning 
by limiting dilution. Stably silenced clones were established from 
shSLAMF1#1 and from a mixture of the 3 shRNAs. No differences 
in the expression of line-specific markers (CD19, CD20, CD23, 
responses. This hypothesis is indirectly supported by the finding that 
many cancer therapeutics act by activating autophagy.
Signaling-lymphocytic-activation-molecule-family1 (SLAMF1) 
is the prototype member of a family of 9 genes that code for adhe-
sion/costimulatory molecules that initiate signal transduction net-
works in T, natural killer, and antigen-presenting cells (17, 18). Dur-
ing T-B lymphocyte cross-talk, SLAMF1 works as a self-ligand and 
mediates a signal transduction pathway that enhances lymphocyte 
activation (19). In murine macrophages, SLAMF1 was found to con-
trol the killing of Gram-negative bacteria, by regulating phagosome 
functions through the recruitment of VPS34 and beclin1 (20).
In this work, we show that circulating CD19+/CD5+ normal 
B-lymphocytes, considered the normal counterpart of CLL (21), 
constitutively express SLAMF1. SLAMF1 expression is maintained 
in CLL cells associated to a favorable prognosis. It is instead lost 
in a subset of patients who have an aggressive form of the disease 
characterized by shorter time to first treatment and OS. We also 
demonstrate that SLAMF1 activates the autophagic flux by modu-
lating a signaling circuit that involves ROS generation, activation 
of JNK1/2, BCL2 phosphorylation, and ultimately association with 
beclin1 and VPS34 to stabilize the autophagic macrocomplex. In 
line with these observations, SLAMF1-deficient CLL cells are 
resistant to the action of autophagy-inducing therapies.
Results
SLAMF1 is heterogeneously expressed by CLL cells. Studies of surface 
antigen and gene expression profiling performed on limited sets of 
CLL patients showed that SLAMF1 is preferentially expressed by 
CLL cells bearing molecular markers of favorable prognosis (22–24).
In this work, SLAMF1 expression was evaluated in the CD19+ 
subset of a cohort of 300 CLL patients with a confirmed diagnosis of 
CLL and well-characterized clinical and molecular features (Supple-
mental Table 1; supplemental material available online with this arti-
cle; doi:10.1172/JCI83013DS1). Expression was markedly hetero-
geneous with a median of 40% SLAMF1+ cells (Figure 1, A and C). 
This heterogeneity in expression was confirmed at the mRNA level 
(Supplemental Figure 1A). On the contrary, circulating CD19+/CD5+ 
B-lymphocytes from nonleukemic adult donors, considered the nor-
mal counterpart of CLL cells (21), were invariably SLAMF1+ (Figure 
1, B and C, and Supplemental Figure 1A), with a median expression 
of 91%, independently of CD27 expression (Supplemental Figure 
1D) and in line with previous results (25). Forty-two patients were 
then tested for SLAMF1 expression on 2 different occasions at least 
3 months apart (range 3–15 months), with no intervening therapy. 
Under these conditions, expression of the molecule was generally 
stable over time (Supplemental Figure 1B). Surface SLAMF1 showed 
a linear correlation with mRNA levels, in line with a direct relation-
Table 1. TFS and OS of CLL patients categorized on the basis of SLAMF1 expression
TFS OS
Events Total Median 95% CI Events Total 10 years 95% CI
SLAMF1 > 6% 92 209 7.6 yr 5.3–9.8 11 233 94.7% 91.4–98.6
SLAMF1 ≤ 6% 30 45 2.2 yr 0–4.8 6 45 77.5% 58.9–96.1
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Figure 1. SLAMF1 expression is lost in a subset of CLL patients with a more aggressive form of the disease. (A) Dot plots showing CD19/SLAMF1 expres-
sion in 3 representative CLL patients. (B) SLAMF1 expression was analyzed in the CD19+/CD5+ fraction of PBMC preparations from normal donors. (C) Box 
plot showing cumulative data from 300 CLL patients and 12 normal donors. (D) Distribution of SLAMF1 expression according to disease stage or treatment 
conditions. Patients were grouped into stage A versus stages B+C, according to the Binet classification. (E) Distribution of SLAMF1 expression according 
to treatment (chemotherapy or chemoimmunotherapy). –, untreated; +, treated with chemotherapy or chemoimmunotherapy. The box plot on the right 
considers patients who received no treatment for a period of at least 60 months, as opposed to patients who were treated within 1 year of diagnosis. (F) 
Distribution of SLAMF1 expression according to molecular and cytogenetic markers. The mutational status of the IGHV genes (unmutated if >98% similar 
to the germline sequence) together with CD38 and CD49d expression were considered as molecular markers. The cut-off for CD38 and CD49d expression 
was 30%. When considering cytogenetic abnormalities, patients were grouped on the basis of favorable (13q- or no abnormalities) vs. unfavorable (11q- 
and 17p-) chromosomal deletions. (G) Kaplan Meyer curves showing the probability of TFS and OS of CLL patients categorized on the basis of SLAMF1 
expression. The 6% cut-off was determined by recursive partitioning analysis. Statistical analyses (C–F) were performed using Mann-Whitney U test.
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rogation of the 1,281 differentially expressed annotated genes 
using functional online tools showed marked enrichment for bio-
logical processes involved in vesicle trafficking/endocytosis, intra-
cellular signaling, cell death/apoptosis, immune response/activa-
tion, response to stress and adhesion/motility (Figure 2, C and D).
Among these processes, we selected for further analyses the 
panel of genes in the adhesion motility category and those in the 
HLA-II) between the 2 cell lines or with the parental line were 
observed (not shown). Downregulation of SLAMF1 was confirmed 
using quantitative PCR (qPCR) (Figure 2A), immunofluorescence 
and Western blot (Supplemental Figure 3, C and D).
By applying global gene expression analysis, we observed that 
Mec-1/Ctrlsh and Mec-1/SLAMF1sh have distinct profiles, with 623 
upregulated and 766 downregulated sequences (Figure 2B). Inter-
Figure 2. Loss of SLAMF1 expression is 
associated with the modulation of genetic 
pathways regulating cell movement and 
vesicle trafficking. (A) qPCR data showing 
stable downregulation of SLAMF1 mRNA in 
Mec-1 cells transfected with SLAMF1 shRNA 
and selected by sorting and limiting dilution 
cloning. Data from at least 5 independent 
experiments. (B) Comparison of the gene 
signature of Mec-1/Ctrlsh vs. Mec-1/SLAMF1sh 
cell clones. The light gray area in the Venn 
diagram identifies upregulated genes 
and the dark gray identifies downregu-
lated genes in the Mec-1/Ctrlsh vs. Mec-1/
SLAMF1sh. (C) Histogram plot showing the 
absolute number of genes modulated in the 
most representative functional categories 
identified by pathway-enrichment analysis. 
(D) Heat map of 419 transcripts differen-
tially expressed in the comparison between 
Mec-1/Ctrlsh and Mec-1/SLAMF1sh belonging 
to vesicle trafficking/endocytosis category. 
Red, increased expression; green, decreased 
expression. (E and F) qPCR data showing 
expression of SLAMF1, CXCR4, CD38, and 
CD44 in purified CLL cells from SLAMF1+ 
(n = 22) and SLAMF1– (n = 16) patients. 
(G) Results from chemotaxis experiments 
against CXCL12 of primary CLL cells derived 
from SLAMF1+ (n = 22) and SLAMF1– (n = 16) 
patients. (H) qPCR data showing expression 
of CXCR3 and SELL in purified CLL cells 
from SLAMF1+ (n = 22) and SLAMF1– (n = 16) 
patients. The graph on the right shows the 
results of a chemotaxis experiment against 
CXCL10 performed using primary CLL cells 
derived from SLAMF1+ (n = 6) or SLAMF1–  
(n = 6) cells. MI, migration index, calculated 
as the ratio between the number of CD5+/
CD19+ cells transmigrating in the presence 
and absence of CXCL12. RE, relative expres-
sion. Statistical analyses (A, E–H) were 
performed using Mann-Whitney U test.
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complex in mouse macrophages (20), prompted us to ask whether 
SLAMF1 activation could directly modulate autophagy in primary 
CLL cells. When autophagy is activated, the LC3B-I molecule 
(also known as Atg8) is cleaved, lipidated, and inserted as LC3B-II 
into the nascent autophagosome membrane. Cross-linking of 
SLAMF1 using an agonistic monoclonal antibody in purified CLL 
cells significantly increased endogenous LC3B aggregation and 
the amount of lipidated LC3B-II species when compared with 
untreated cells, as shown by confocal and by Western blot anal-
yses (Figure 3, C and D). However, given that the autophagosome 
is an intermediate structure in a dynamic pathway, the number of 
autophagosomes observed at any given time is a function of the 
balance between the rate of their generation and the rate of their 
conversion into autolysosomes (34). Therefore, to determine the 
autophagic flux, chloroquine was used to block lysosomal acid-
ification, leading to the inhibition of autophagosome turnover. 
The autophagic flux was represented as the difference between 
the intensity of the LC3B-II band in the SLAMF1 plus chloroquine 
condition versus the SLAMF1-alone condition or the chloro-
quine-alone versus the untreated condition (indicated in Fig-
ure 3D as ΔLC3-II), as reported (35). The finding of significantly 
increased amounts of LC3B-II species in SLAMF1-activated and 
chloroquine-treated primary CLL cells clearly showed that LC3B-II 
protein starts to accumulate upon SLAMF1 ligation (Figure 3D). 
The autophagosome then fuses with the lysosome, which can be 
visualized using the specific marker LAMP-2. The autophagolys-
osome can therefore be recognized by the simultaneous expres-
sion of LC3B and LAMP-2. LC3B puncta, which were clearly vis-
ible using confocal microscopy, almost completely overlapped 
with the lysosomal marker LAMP-2, confirming that the process 
is complete (Figure 3C). Thus, SLAMF1 promotes the autophagic 
flux in primary CLL cells. Similar results were observed using the 
Mec-1 cell line (Supplemental Figure 6, A and B). In addition, when 
using Mec-1 cells, the degradation of p62, a common target of the 
autophagic process, was apparent (Supplemental Figure 6B).
Electron microscopy analysis of primary CLL cells activated 
through SLAMF1 revealed the widespread appearance of elec-
tron-dense membrane-delimited bodies within the cytoplasm, with 
characteristic autophagic profiles. Some of them appeared to be 
early double-membrane autophagosomes (full arrow), while others 
— often close to multivescicular bodies (arrowhead) — seemed to 
be late autophagosomes (open arrow). The latter were more visible 
after SLAMF1 cross-linking and were delimited by a single mem-
brane, with electron-dense content, including partially degraded 
ribosomes, showing up as dark granular clumps (Figure 3E).
These results demonstrate that ligation of SLAMF1 activates the 
autophagic process both in primary cells and in a reference cell line.
Molecular mechanisms behind SLAMF1-driven autophagy. 
Autophagy can be initiated by a number of signals and conditions, 
but the cellular redox status is believed to play a critical role (36). 
Cross-linking of SLAMF1 with an agonistic mAb induced ROS 
accumulation, commencing 30 minutes after antibody binding 
and reaching its maximal accumulation after 18 hours in primary 
CLL cells (Figure 4A). Specifically, we used flow cytometry to mea-
sure the amount of intracellular hydrogen peroxide (H2O2) with the 
5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate 
(CM-H2DCFDA). CM-H2DCFDA is a widely used indicator of oxi-
vesicle trafficking/endocytosis category. This choice was based 
on the existence of previous data functionally linking SLAMF1 to 
these processes. Mec-1/SLAMF1sh cells from each clone showed a 
significant difference in genes involved in cell migration, as com-
pared with both Mec-1/Ctrlsh and Mec-1/WT. Upmodulation of 
CXCR4, the CXCL12 receptor, was confirmed both at the mRNA 
and protein levels (Supplemental Figure 4A). The CD38 ecto- 
enzyme, which was found to associate with CXCR4 and to posi-
tively regulate CXCL12 signaling (26, 27), was similarly upregu-
lated (Supplemental Figure 4B). Moreover, we found increased 
expression of CD44, an adhesion molecule that forms part of the 
CLL invadosome and that controls migration of CLL cells (Supple-
mental Figure 4C and refs. 28, 29). These data were confirmed by 
comparing primary CLL cells expressing SLAMF1 ≤ 6% or SLAMF1 
> 6% cut-off, as also confirmed at the mRNA level (Figure 2E). In 
this cohort, CXCR4, CD38, and CD44 were significantly more 
expressed in the SLAMF1 ≤ 6% subset (Figure 2F). Consistent with 
this phenotype, Mec-1/SLAMF1sh cells showed higher chemotaxis 
toward CXCL12 than the Mec-1/Ctrlsh cells (Supplemental Figure 
4D). Likewise, when studying CXCL12-driven chemotaxis in a 
cohort of 38 primary CLL cases, those expressing SLAMF1 ≤ 6% 
showed a significantly higher migration index than the rest of the 
cohort (Figure 2G). Lastly, when analyzing chemotactic responses 
in primary CLL cells with a bimodal SLAMF1 expression, it was 
clear that the SLAMF1lo component showed more efficient chemo-
taxis toward CXCL12 than the SLAMF1hi one (Supplemental Fig-
ure 4E). Silencing of SLAMF1 in Mec-1 was also followed by a sig-
nificant decrease, both at mRNA and protein levels, in CXCR3 and 
in CD62L (SELL) (Supplemental Figure 4, F and G), two molecules 
highly expressed in subsets of patients with a favorable prognosis 
(30, 31). Decreased CXCR3 and CD62L expression was confirmed 
in primary CLL cells (Figure 2H). In line with this phenotype, Mec-1/ 
SLAMF1sh cells and SLAMF1– primary CLL cells showed reduced 
migration toward CXCL10, as opposed to Mec-1/Ctrlsh (Supple-
mental Figure 2H) or SLAMF1+ primary CLL cells (Figure 2H).
Of the 1,281 modulated genes, approximately one-third (n = 419) 
were part of the functional vesicle trafficking/endocytosis cate-
gory. Among them, Mec-1/SLAMF1sh cells showed a marked down-
modulation of vimentin (VIM), a cytoskeletal protein that can regu-
late protein trafficking and autophagy (32), and of VPS34 (PIK3C3), 
a member of the PI3K family responsible for autophagosome for-
mation and accumulation (33) (Supplemental Figure 5, A and B). 
These differences were maintained in primary CLL cells and con-
firmed at the protein level (Figure 3A). Reconstitution of SLAMF1 
expression by transfection of a cDNA encoding an shRNA-resistant 
human SLAMF1 (Supplemental Figure 5, C and D) was followed by 
rescued expression of vimentin and VPS34, further ruling out the 
possibility of off-target effects (Figure 3B).
Considered together, these data suggest that SLAMF1 silenc-
ing is followed by a significant upmodulation of proteins regulat-
ing migration and a downmodulation of molecules involved in 
intracellular vesicle formation, suggesting that these 2 biological 
processes are relevant in determining the inferior clinical perfor-
mance of SLAMF1– patients.
SLAMF1 promotes the autophagic flux. The modulation of genes 
involved in vesicle formation, together with previous reports indi-
cating that SLAMF1 regulates the assembly of the autophagic 
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Figure 3. Cross-linking of SLAMF1 in 
CLL cells stabilizes the autophagic 
flux. (A) qPCR and Western blot 
showing vimentin and VPS34  
mRNA and protein expression by 
Western blot in primary SLAMF1+  
(n = 9) or SLAMF1– (n = 14) CLL 
cells. (B) Reconstitution of SLAMF1 
expression in Mec-1/SLAMF1sh cells 
by transfection of a shRNA-resistant 
SLAMF1 mutant (mut2) or an empty 
vector (mock). Data are presented as 
the ratio between expression of the 
target gene in Mec-1/Ctrlsh cells over 
that of Mec-1/SLAMF1sh cells (gray 
bars) or the ratio between Mec-1/
SLAMF1sh/mut2 cells over Mec-1/
SLAMF1sh/mock transfected cells 
(open bars). The graph shows results 
from 4 independent transfection 
experiments. (C) Confocal microscopy 
analysis of LC3B (green) and LAMP-2 
(red) staining in purified CLL cells 
treated with the agonistic anti-
SLAMF1 monoclonal antibody A12, 
followed by a cross-linker (6 hours, 
37°C). Nuclei were counterstained 
with DAPI (blue). Original magnifica-
tion, ×63; zoom factor of 2. Repre-
sentative images from 5 different 
experiments. Scatter plots represent 
colocalization analyses between LC3B 
and LAMP-2 using LAS AF Version 
Lite 2.4 software. Pearson coefficient 
(R) and Overlap coefficient (R[r]) are 
listed. The box plot shows cumulative 
numbers of LC3B puncta (calculated 
as average number of puncta/cell) 
in purified CLL cells from 5 differ-
ent patients. LAMP-2 mean pixel 
intensity was analyzed using ImageJ 
software. (D) Western blot analysis 
of LC3B-I/II expression, following 
SLAMF1 cross-linking in the presence 
or absence of chloroquine (Chloro, 15 
μM). ΔLC3B-II levels were calculated 
as the difference of LC3B-II protein 
levels between chloroquine-treated 
and untreated states. Data from 
8 independent experiments. (E) 
Electron microscopy analysis of CLL 
cells treated with SLAMF1 antibody 
as in C. Upon SLAMF1 ligation, 
autophagosomes became visible 
as double membranes surrounding 
cytoplasmic material (full arrow). Late 
autophagosomes were visualized as a 
single membrane surrounding a more 
electron-dense interior (open arrow), 
in proximity to multivesicular bodies 
(MVB, arrowhead). Scale bars: 0.5 μm. 
UT, untreated. Mann-Whitney U test 
(A, C) or Wilcoxon signed rank test (D) 
were used.
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dative stress (37) and becomes fluorescent upon oxidation by H2O2 
or free radicals downstream. These results were confirmed in the 
Mec-1 cell line with the CM-H2DCFDA probe (Supplemental Fig-
ure 7A) and with the CellROX assay (Figure 4B), also suitable for 
GFP+ cells. ROS production following SLAMF1 cross-linking was 
impaired after silencing of gp91-phox or p40-phox subunits of the 
NADPH oxidase 2 (NOX2) complex (Figure 4B and Supplemen-
tal Figure 7B), confirming that NOX2 is responsible for SLAMF1- 
induced ROS generation, as observed in other models (20, 38).
Activation of the MAP kinases, particularly of JNK1/2 and of 
p38, is critical during autophagic execution and has been directly 
linked to an increase in intracellular ROS production (39, 40). 
Cross-linking of SLAMF1 was followed by a prominent tyrosine 
phosphorylation of JNK1/2 (p46 and p54 isoforms, Thr183/Tyr185) 
and of p38 (Thr180/Tyr182), which started after 1 minute and 
peaked after 10 minutes, with highly reproducible kinetics in the 
8 patients studied (Figure 4C). Overlapping results were obtained 
after SLAMF1 activation in Mec-1 cells (Supplemental Figure 7C).
The execution of autophagy relies on the assembly of the 
autophagosome macrocomplex, which contains the scaffold pro-
tein beclin1, the enzyme VPS34 and UVRAG, and various other 
proteins (41, 42). However, under steady state conditions, beclin1 
Figure 4. SLAMF1 cross-linking induces ROS accumulation, activates JNK1/2 and p38 kinases, and phosphorylates BCL2. (A and B) SLAMF1 cross-link-
ing induces ROS accumulation, as measured by flow cytometry in CLL cells (A) or Mec-1 cells (B) by using CM-H2DCFDA or CellRox dies, respectively. The 
histogram on the left shows results from a representative experiment. The bar graph in A derives from 8 independent experiments using primary cells 
from 8 different patients. Silencing of gp91-phox or p40-phox of the NOX2 enzyme complex by siRNA transfection impairs ROS accumulation following 
SLAMF1 cross-linking in Mec-1 cells (B). The Western blot confirms silencing of both molecules. Results from 5 independent experiments, each performed 
in triplicate. (C) Ligation of SLAMF1 on primary CLL cells induces time-dependent tyrosine phosphorylation of JNK1/2 and p38. A representative blot is 
shown, together with cumulative data obtained from 8 independent experiments from 8 different patients. The fold-increase represents the increase in 
band intensity over the untreated condition. (D) Ligation of SLAMF1 induces a rapid and robust phosphorylation of BCL2 at S70 in primary CLL cells, as 
shown with a specific mAb. The bar graph shows cumulative data from 7 different patients. (E) Confocal microscopy showing p-BCL2 accumulation (green) 
following SLAMF1 ligation in primary CLL cells. The cytoskeleton was visualized by AlexaFluor 568–conjugated phalloidin; nuclei were counterstained with 
DAPI. Original magnification, ×63; zoom factor of 2. Representative image from 5 independent experiments. ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05, as 
calculated by Friedman’s test followed by Dunn’s multiple comparison.
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Figure 5. Use of selective inhibitors to highlight sequential steps in the SLAMF1-induced autophagy. (A) Effects of the pretreatment with SP600125 (JNK1/2 
inhibitor, 15 μM), NAC (ROS scavenger, 5 mM), or DPI (NOX2 inhibitor, 0.05 μM) in the phosphorylation of BCL2, JNK1/2, and the appearance of lipidated LC3B 
induced upon SLAMF1 ligation in Mec-1 cells. Representative gel from 8 different experiments. The percentage of inhibition was calculated as: 100 (intensity of 
phosphorylated protein/control protein), after considering 100% of the value obtained in the SLAMF1-alone condition. (B and C) Confocal microscopy of primary 
CLL cells showing the effects of SP600125 (5 μM), NAC (2.5 mM) and DPI (0.05 μM) on the phosphorylation of BCL2 (B) and on LC3B (C) induced upon SLAMF1 
ligation. Original magnification, ×63; zoom factor of 2. The box plot shows mean pixel intensity of BCL2 signal or cumulative numbers of LC3B puncta (calculated 
as average number of puncta/cell) in purified CLL cells from 3 different patients treated as described. (D) Bar graph showing the percentage of inhibition in ROS 
accumulation following SLAMF1 cross-linking in the presence of NAC and DPI, considering the level of ROS in the SLAMF1-alone condition to be 100%. ROS accu-
mulation was measured with the CellROX probe. (E) Immunoprecipitation experiments performed in Mec-1 cells after cross-linking SLAMF1 with the A12 antibody 
(30 minutes, 37°C). Where indicated, SP600125 (SP) was added. The right image is representative of an immunoprecipitation experiment with an anti-SLAMF1 
or an isotype-matched irrelevant antibody and subsequent immunoblot for beclin1 and VPS34. Whole cell lysate (WCL) is shown in the first lane. Representative 
images from 3 independent experiments. Statistical significance was calculated using Friedman’s test followed by Dunn’s multiple comparison. ****P ≤ 0.0001, 
***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05.
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strated by the colocalization between LC3B and LAMP-2 and by 
the degradation of p62 (Figure 6, B and C). In contrast, Mec-1/
SLAMF1sh showed limited increase in ROS levels, with no modu-
lation of the autophagic flux or p62 degradation (Figure 6, A–C). 
Consequently, treatment of Mec-1/Crlsh cells with both drugs used 
at therapeutic concentrations induced apoptosis, while Mec-1/ 
SLAMF1sh appeared resistant (Figure 6D). These results link 
SLAMF1 to the activation of drug-induced autophagy in CLL cells.
Confirmation was obtained using primary cells, where 
SLAMF1hi CLL cells underwent significantly more apoptosis 
than SLAMF1lo ones in response to ABT-737 (Figure 6E). Like-
wise, apoptosis in response to fludarabine was markedly higher 
in SLAMF1hi than in SLAMF1lo cells. These results were con-
firmed after sorting the same primary CLL clones with a bimodal 
SLAMF1 distribution, allowing for comparison of SLAMF1hi and 
SLAMF1lo cells with the same clonal origin (Figure 6E). Results 
from 5 different patients make it clear that the SLAMF1lo com-
ponent of the clone is significantly more resistant to apoptosis 
than its counterpart (Figure 6E). No patients with del17p were 
included in this study, to eliminate confounding elements.
Together, our results demonstrate that loss of SLAMF1 
expression from the cell surface affects spontaneous and drug- 
induced autophagy responses, making these cells resistant 
to therapy and potentially explaining the unfavorable clinical 
behavior of SLAMF1-deficient CLL clones.
Discussion
In cancer, autophagy can participate in both tumor suppression 
and progression mechanisms. Depending on the cellular context, 
autophagy may enable tumor cells to survive chemotherapy-medi-
ated stress, or it may maintain cellular homeostasis by removing 
damaged organelles and preventing the genomic damage that 
leads to cancer (51–53). In leukemia, several studies have shown 
that autophagy is activated upon treatment with different chemo-
therapeutic agents, inducing cell death. This is true also for CLL, 
where many currently used drugs — including fludarabine, dex-
amethasone, idelalisib, and the novel BCL2 antagonists (54–56) 
— have been suggested as having an autophagy-mediated effect.
This work connects the expression of the surface receptor 
SLAMF1 to the modulation of chemotactic responses, providing 
support to the hypothesis that the ability of cells to localize in a 
growth-favorable environment conditions disease aggressiveness. 
The second observation of this work is that SLAMF1 regulates an 
intracellular autophagic pathway, which is in turn important in dic-
tating therapeutic responses. In agreement with previous obser-
vations (25), our findings confirm that normal B-lymphocytes 
uniformly express SLAMF1 at high levels, including the CD19+/
CD5+ subset. However, as expected on the basis of gene expres-
sion profiling studies (22–24), SLAMF1 expression in the patient 
cohort studied was highly variable. Reduced SLAMF1 levels typi-
cally associated with clinical or molecular markers of unfavorable 
prognosis, including a more advanced stage of disease, absence 
of mutations in the IgV genes, and surface expression of CD38 
and of CD49d. As such, the patient subset expressing SLAMF1 
≤ 6% (≈15% of the cohort examined) was characterized by a sig-
nificantly shorter time to first treatment and OS. It is important 
to note that SLAMF1– patients needed therapy significantly earlier 
is bound to the antiapoptotic protein BCL2 and is consequently 
inactive (33, 43, 44). Phosphorylation of critical threonine and 
serine residues in BCL2 triggers a conformational change in the 
molecule, which leads to its dissociation from beclin1 (45, 46). 
SLAMF1 cross-linking was followed by a prominent phosphory-
lation of BCL2 at serine 70 (S70) (Figure 4D), which was already 
evident after 1 minute of receptor engagement. This result was 
obtained using patient-derived cells and confirmed in the Mec-1 
cell line model (Supplemental Figure 7D). BCL2 phosphoryla-
tion could also be confirmed using confocal microscopy, clearly 
indicating that the molecule is still phosphorylated 6 hours after 
SLAMF1 cross-linking, consistent with the appearance of autoph-
agic vesicles (Figure 4E and Supplemental Figure 7E).
These findings suggest that a possible mechanism connect-
ing SLAMF1 to the autophagy machinery relies on generation of 
ROS and activation of JNK1/2, which would then phosphorylate 
BCL2, dissociating it from beclin1 and leaving it free to assemble 
the autophagic complex. Proof of concept was obtained by using 
a JNK1/2 inhibitor, a ROS scavenger, and DPI as a specific NOX2 
inhibitor. BCL2 phosphorylation was blocked after treatment 
with the JNK1/2 inhibitor SP600125, the ROS scavenger NAC, 
and the NOX2 inhibitor DPI (Figure 5A). Inhibition of BCL2 
phosphorylation was maintained for at least 6 hours, as shown 
by confocal microscopy using primary CLL cells (Figure 5B). All 
3 inhibitors interfered with JNK1/2 phosphorylation and with the 
activation of autophagy, as determined by Western blot and by 
confocal microscopy (Figure 5C and Supplemental Figure 8, A 
and B), confirming that BCL2 phosphorylation is critical for the 
induction of SLAMF1-triggered autophagic flux. The finding of 
impaired ROS production upon DPI treatment confirmed that 
NOX2 contributes, at least in part, to ROS production in SLAMF1- 
treated CLL cells (Figure 5D).
Coimmunoprecipitation experiments showed that SLAMF1 
cross-linking was followed by a marked dissociation of the BCL2/
beclin1 complex. Incubation with the JNK1/2 inhibitor SP600125 
substantially prevented BCL2/beclin1 dissociation, suggesting that 
this is the main molecular mechanism involved in the activation 
of autophagy (Figure 5E). Simultaneously, upon SLAMF1 ligation, 
there is an increased association of beclin1 to VPS34, partially abro-
gated by inhibiting JNK1/2 (Figure 5E). Lastly, SLAMF1 was found 
to interact directly with the autophagic complex, as inferred from 
the association between SLAMF1, VPS34, and beclin1 (Figure 5E).
SLAMF1– cells are more resistant to autophagy-inducing therapies. 
Besides maintaining cellular homeostasis under normal growth 
conditions, autophagy critically controls cellular responses to stress-
ful conditions (47, 48). We therefore investigated whether loss of 
SLAMF1 affects responses to drugs known to activate autophagy, 
such as fludarabine or the BH3 mimetic ABT-737. Fludarabine is a 
commonly used chemotherapeutic agent in CLL (49), while ABT-737 
is the prototype of a novel family of molecules that activate autoph-
agy by causing the dissociation of the BCL2/beclin1 complex (50).
Exposure of Mec-1/Ctrlsh or Mec-1 WT cells to fludarabine or 
ABT-737 was followed by a sharp increase in ROS levels and by the 
activation of autophagy (Figure 6, A and B). Immunostaining anal-
ysis for LC3B in Mec-1/Ctrlsh cells treated with fludarabine or with 
ABT-737 for 5 hours showed an increase in the number of LC3B 
puncta and a complete execution of the autophagy flux, as demon-
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Figure 6. SLAMF1-deficient cells are resistant to drugs that activate autophagy. (A) ROS production upon 5 hour culture of Mec-1/Ctrlsh (white bars) and 
Mec-1/SLAMF1sh (gray bars) in the presence of fludarabine (100 μM) or ABT-737 (10 μM). ROS were measured using the CellROX assay and are shown as 
mean fluorescence intensity (MFI) values. Statistical significance was calculated using Friedman’s test followed by Dunn’s multiple comparison using 
data from 5 independent experiments performed in triplicate. *P < 0.05; **P < 0.01. (B and C) Induction of autophagy after 5-hour cultures with fludara-
bine or ABT-737 was shown in Mec-1/Ctrlsh and Mec-1/SLAMF1sh by staining for LC3B (green) and LAMP-2 (red), followed by confocal microscopy analysis 
(original magnification, ×63; zoom factor of 2) (B) or by Western blot for LC3B and p62 (C). Cells were pretreated with chloroquine for 1 hour to block the 
autophagic flux. ERK1/2 was used as internal loading control. ΔLC3B-II was calculated as indicated in Figure 3D. The fold-change was calculated over the 
untreated condition. The p62 fold-change was calculated after normalizing p62 over ERK1/2, with the untreated condition set to 1. Data from 6 experi-
ments. (D) Bar graph showing apoptosis levels in Mec-1/Ctrlsh and Mec-1/SLAMF1sh cultured in the presence of fludarabine (100 μM) or ABT-737 (10 μM) 
for 48 hours. The percentage of apoptosis was calculated as the sum of cells stained by Annexin V and by propidium iodide (PI). (E) Primary CLL cells  
(n = 5) with a bimodal distribution of SLAMF1 were separated by cell sorting in a SLAMF1hi and a SLAMF1lo subset. The 2 sorted subpopulations were cul-
tured for 24 hours in the presence of fludarabine 5 μM or ABT-737 (10 nM), and cell death was determined by Annexin V/PI staining. Statistical analyses 
were performed using Mann-Whitney test.
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osomes. The finding that autophagy was induced upon SLAMF1 
cross-linking with an agonistic monoclonal antibody suggests 
that the antibody is standing in for a physiological ligand, possi-
bly a second SLAMF1 molecule. If this is true, then it is reasonable 
to speculate that SLAMF1-SLAMF1 interactions, which occur 
regularly during normal T-B lymphocyte interactions, would 
promote autophagy, a mechanism that is increasingly being rec-
ognized as important in the regulation of lymphocyte prolifera-
tion, energy metabolism, and cell death (61–63). The molecular 
cascade connecting SLAMF1 to the activation of autophagy relies 
on the accumulation of ROS, the activation of the MAP kinases, 
and the phosphorylation of BCL2. This last step causes the disso-
ciation between BCL2 and beclin1 and the consequent assembly 
of the autophagic macrocomplex, which contains SLAMF1 itself, 
beclin1, and VPS34. While we cannot exclude the participation 
of other molecular mechanisms to the formation of the autoph-
agy macrocomplex, the use of specific inhibitors indicates that 
BCL2 phosphorylation and consequent dissociation from beclin1 
is certainly involved.
The third finding of this work is that the expression of SLAMF1 
conditions responses to therapeutic agents that act by modulating 
autophagy. This has been conclusively shown for fludarabine (54) 
and for a novel class of therapeutic agents that act by causing the 
degradation of BCL2 (64). The prototype of these drugs is ABT-
737, which induces the dissociation between BCL2 and beclin1, 
directly activating autophagy (65). Our experiments indicated 
that Mec-1/SLAMF1sh clones displayed marked resistance to flu-
darabine- or ABT-737–induced apoptosis. Furthermore, when 
examining primary cells from patients, it was clear that SLAMF1lo 
cells were significantly more resistant to fludarabine or ABT-737 
than their counterparts, as confirmed by comparing the responses 
in SLAMF1hi and SLAMF1lo subclones, obtained from the same 
CLL patient. Consistent with the hypothesis that the autophagic 
response is blocked, ROS levels were significantly lower in the 
Mec-1/SLAMF1sh cells than in the controls.
The evidence presented in this paper indicates that SLAMF1 
plays as a critical role in CLL homeostasis. Loss of SLAMF1 
expression changes the chemotactic responses of CLL cells, 
likely favoring homing to growth-favorable districts, a process 
driven by CXCL12. Furthermore, SLAMF1– cells show impair-
ment in the activation of autophagy, which limits their responses 
to a wide array of therapeutic agents. Restoring SLAMF1 expres-
sion in CLL cells would therefore be of therapeutic value for 
patients with aggressive CLL.
Methods
Patients and cells. Blood samples were obtained after informed con-
sent. Patient characteristics are reported in Supplemental Table 1. 
Blood samples of healthy donors (HD) of a comparable age were 
obtained through the local blood bank. Purified B-lymphocytes were 
prepared as described (27). Full details are provided in Supplemental 
Methods. CLL cells were obtained from previously untreated patients 
or from patients who had not been treated in the previous 6 months. 
The treatment regimens used are listed in Supplemental Table 1. The 
Mec-1 cell line was obtained from DSMZ.
Cells were cultured in RPMI-1640 + 10% FCS and antibiotics 
(Sigma-Aldrich).
than their counterparts, providing an initial link between SLAMF1 
expression and treatment requirement. The conclusion from this 
first part of the work is that a subset of CLL patients with clinical 
and molecular hallmarks of aggressive disease is characterized 
by reduced SLAMF1 expression. The finding of a direct relation-
ship between the percentage of SLAMF1+ leukemic cells and the 
number of mRNA copies favors the hypothesis of a transcriptional 
downregulation of the gene in the negative subset of patients, 
even if the molecular mechanism is currently unknown.
The analysis of the transcriptome of Mec-1 cells with a sta-
bly silenced SLAMF1 showed that a significant number of the 
modulated genes are involved in cytoskeletal movements and in 
vesicle trafficking. These modifications were maintained at the 
protein level, suggesting functional implications; in fact, Mec-1/ 
SLAMF1sh cells migrated significantly more in response to 
CXCL12 and significantly less in response to CXCL10. Increased 
expression of the CXCR4 receptor and of CD38, a surface 
enzyme that enhances chemotactic responses (57), on the one 
side and decreased expression of CXCR3 on the other provide a 
partial explanation to this phenomenon. Considering the marked 
differences between the Mec-1 cell line and primary CLL cells in 
terms of phenotype (e.g., lack of CD5 expression in the cell line) 
and growth properties (e.g., exponentially growing line with a 
duplication time of about 20 hours), we confirmed these findings 
in primary cells. By analyzing the migration index of a cohort of 
CLL patients, it became clear that samples with expression of 
SLAMF1 ≤ 6% migrated significantly more toward CXCL12. This 
difference was maintained when comparing the SLAMF1hi ver-
sus SLAMF1lo components of the same CLL clone, which share a 
genetic structure. Likewise, primary SLAMF1lo primary CLL cells 
migrated less in response to CXCL10, a feature that has been 
linked to a favorable clinical behavior of the leukemia (30). These 
results link the loss of SLAMF1 expression to the modulation of 
expression of molecules involved in CLL recirculation to the lym-
phoid organs, suggesting that this behavior may be responsible, at 
least partially, for the more aggressive clinical course in SLAMF1lo 
than in SLAMF1hi patients. Loss of vimentin in the SLAMF1lo sub-
set, while difficult to interpret at the light of controversial data 
on the role of this protein in leukemia, suggests that tumor cells 
undergo a radical reorganization of their cytoskeleton (58, 59). A 
link between SLAMF1 expression and the regulation of cell move-
ment was recently proposed to rely on the modulation of ROS lev-
els, suggesting that different members of the SLAMF family have 
contrasting properties related to their ability to induce ROS (38). 
In agreement with those results, we observed downregulation of 
ROS levels in Mec-1/SLAMF1sh cells.
The second finding from gene expression profiling indicates 
profound modulation of pathways connected with vesicle forma-
tion and recirculation. Loss of SLAMF1 affected the expression of 
a number of molecules that critically regulate this signaling cas-
cade, including VPS34 itself and vimentin. According to published 
data, beclin1 would serve as a scaffold for the formation of the 
autophagic complex, while vimentin would be essential in anchor-
ing the vesicles to the cytoskeleton (60).
Intriguingly, cross-linking of SLAMF1 with an agonisic mAb 
in primary cells and in a representative cell line enhanced the 
generation of autophagic vesicles and their fusion with the lys-
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plemental Methods. All reactions were performed in triplicate. The 
threshold cycle (CT) method was used to calculate expression rela-
tive to the endogenous control.
Chemotaxis assay. Chemotaxis assays were performed using the 
Boyden chamber assay, as described (26). Full details are provided in 
Supplemental Methods.
Western blot and immunoprecipitation studies. Full details are pro-
vided in Supplemental Methods.
Autophagy detection. To detect LC3B-II production, cells were 
incubated with anti-SLAMF1 functional grade purified (A12) mAb (1.5 
μg/106 cells), in the presence of coated donkey anti-mouse IgG Ab (10 
μg/ml) or with an irrelevant isotype-matched antibody. Cells were cul-
tured (6 hours, 37°C) in normal medium with or without the lysosome 
inhibitor chloroquine (15 μM), were lysed, and were analyzed by West-
ern blot by using the specific antibody anti-LC3B (1:1000).
For confocal microscopy detection of autophagy, treated cells 
(3 × 105 cells/slide) were centrifuged by cytospin, fixed (4% paraform-
aldehyde, 10 minutes), permeabilized (0.1% saponin, 20 minutes), 
and stained with the indicated antibodies. Nuclei were counterstained 
with DAPI (Invitrogen). Slides were mounted in SlowFade Gold 
reagent (Invitrogen) and analyzed using a TCS SP5 laser scanning 
confocal microscope with 4 lasers (Leica Microsystems); images were 
acquired with LAS AF Version Lite 2.4 software (Leica Microsystems) 
and processed with Adobe Photoshop CS6 software.
For electron microscopy detection of autophagy, purified CLL 
cells (6 × 106) were fixed (2.5% glutaraldheyde in 0.1 M cacodilate 
buffer (pH 7.2), 2 hours, room temperature and then overnight, 4°C), 
rinsed, and dehydrated in an ascending series of ethanol solutions to 
100%. Cells were then infiltrated in Epon-Araldite resin, which poly-
merized (24 hours, 60°C) (66). Embedded samples were processed for 
ultramicrotomy: semithin sections (0.5 μm) were stained with 1% tolu-
idine blue, and ultrathin (70 nm) sections were counterstained with 
uranyl acetate and lead citrate. Samples were examined on a Philips 
CM10 transmission electron microscope.
ROS production. Intracellular ROS production was detected by 
flow cytometry using the redox sensitive dyeCM-H2DCFDA (1 μM, 20 
minutes, 37°C) or the CellROX Deep Red Reagent fluorogenic probe 
(1 μM, 30 minutes, 37°C) following manufacturer instructions. All 
probes were from Molecular Probes (Invitrogen).
For NOX2 inhibition studies, cells were transfected with 60 pmol/
sample of gp91-phox siRNA, p40-phox siRNA, or negative control 
siRNA (all from Santa Cruz Biotechnology Inc.).
Statistics. The cumulative probability of TFS and OS were esti-
mated by recursive partitioning analysis. TFS was defined as the time 
elapsed from date of diagnosis to date of first treatment, and OS was 
defined as the time from first diagnosis to death. The analysis was 
performed with the Statistical Package for the Social Sciences (spss) 
software v.16.0 (SPSS Inc.).
Cumulative data of functional studies are shown as mean val-
ues with standard deviation and statistical significance determined 
using Mann-Whitney U test (unpaired data) or Wilcoxon signed rank 
test (paired data), as appropriate. Matched groups (3 or more) were 
compared using Friedman’s test with Dunn’s multiple-comparisons 
test. Correlation between continuous variables was assessed using 
Pearson’s coefficient.
Data are reported as box plots, where the top and bottom of the 
rectangle define the third and first quartile, respectively, and the whis-
Antibodies and reagents. A list of antibodies and inhibitors used 
is provided in Supplemental Methods. Chloroquine diphosphate was 
from Tocris Bioscience. Protein G-sepharose magnetic beads were 
from GE Healthcare. Fludarabine and the BH3 mimetic ABT-737 
were from Selleckchem.
Generation of SLAMF1-silenced cells. The pGFP-V-RS construct 
for SLAMF1 shRNA (TG309422), a noneffective (scrambled) shRNA 
cassette (TR30013) as a negative control and an empty vector 
(TR3007) were from OriGene. Mec-1 cells were nucleofected with 
3 SLAMF1-specific shRNAs (Supplemental Figure 3A) using the Cell 
Line V Nucleofector Kit (Lonza) and selected by puromycin (Sigma- 
Aldrich). SLAMF1– cells were sorted using a FACSAria III cell sorter 
(BD Biosciences) and cloned by serial dilution. Two clones were 
established from the cells transfected with shRNA#1 (5A4 and 5D7) 
and 1 from the cells transfected with an equimolar mixture of the 3 
shRNAs (3F11). Three different clones for Mec-1/Ctrlsh were used. 
To generate SLAMF1 shRNA–resistant constructs, 3 synonymous 
mutations were introduced into the shRNA#1 targeted region of WT 
SLAMF1 cDNA clone, purchased from OriGene (pCMV6-Entry con-
struct, RC223343). Mutagenesis was performed using QuikChange 
II XL Site-Directed Mutagenesis kit (Agilent Technologies). SLAMF1 
mutants were verified by Sanger sequencing (Supplemental Figure 
5C). Primers used for mutagenesis and sequencing are listed in Sup-
plemental Table 2. The constructs were then transfected into Mec-1/
SLAMF1sh generated from shRNA#1, and expression was verified by 
surface staining with anti-SLAMF1 antibodies, with SLAMF1 mut2 
showing the highest percentages of expression (range 15%–25%) 
(Supplemental Figure 5D). Cells transfected with SLAMF1/mut2 were 
then flow sorted, RNA was extracted, and gene expression was veri-
fied by qPCR. Mock construct pCMV6-Entry (OriGene, PS100001) 
was used as the control.
Gene expression profiling analysis. RNA (300 ng) from Mec-1/
Ctrlsh and Mec-1/SLAMF1sh clones was amplified and biotinylated 
using Illumina TotalPrep RNA Amplification Kit. cRNA (750 ng) 
was hybridized to HumanHT-12 v4 Expression BeadChips using 
Whole-Genome Expression Direct Hybridisation kit and scanned 
with iScan System (Illumina). Scanned image analysis and deter-
mination of the detection call for each probe set were obtained with 
the GenomeStudio Gene Expression Module Software (Illumina), 
applying standard quantile normalization. Expression values were 
background subtracted and filtered against a P value threshold of 
0.01. Unsupervised clustergram analysis of the whole probe set 
was performed using the clustergram tool of the MATLAB bioin-
formatics package (http://www.mathworks.it/), using a Pearson 
correlation coefficient as metric. Lists of differentially expressed 
genes were constructed on probes (i) that simultaneously passed 
the P value threshold in all clones examined and (ii) whose mini-
mum fold-change was higher than one in absolute value (|logFc|>1). 
Analysis of differentially expressed sequences is described in Sup-
plemental Methods. All microarray data have been deposited in 
NCBI’s Gene Expression Omnibus (GEO GSE69165).
RNA extraction and qRT-PCR. RNA was extracted using the 
RNeasy Plus Mini kit (QIAGEN) and converted to cDNA using the 
High Capacity cDNA Reverse Transcription kit (Applied Biosys-
tems, Invitrogen).
qRT-PCR was performed using the 7900 HT Fast Real Time 
PCR system (SDS 2.3 software). A list of primers is provided in Sup-
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